IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂,IC50 为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma[1].
参考文献:
[1]. Degorce SL, et al. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors TargetingMyD88L265P Mutant Diffuse Large B Cell Lymphoma. J Med Chem. 2019 Nov 1.
没有评价数据